BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23640467)

  • 1. ¹⁸F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer.
    Champion L; Lerebours F; Cherel P; Edeline V; Giraudet AL; Wartski M; Bellet D; Alberini JL
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1206-13. PubMed ID: 23640467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
    Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
    Taneja S; Jena A; Goel R; Sarin R; Kaul S
    Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS; Kang DK; Jung YS; Han S; Kim TH
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
    Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.
    An YS; Lee DH; Yoon JK; Lee SJ; Kim TH; Kang DK; Kim KS; Jung YS; Yim H
    Nuklearmedizin; 2014; 53(3):89-94. PubMed ID: 24220324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
    Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and
    Ng SH; Liao CT; Lin CY; Chan SC; Lin YC; Yen TC; Chang JT; Ko SF; Fan KH; Wang HM; Yang LY; Wang JJ
    Eur Radiol; 2016 Nov; 26(11):4162-4172. PubMed ID: 26911889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.
    Groheux D; Giacchetti S; Delord M; Hindié E; Vercellino L; Cuvier C; Toubert ME; Merlet P; Hennequin C; Espié M
    J Nucl Med; 2013 Jan; 54(1):5-11. PubMed ID: 23213197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.